A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

Attarian, S., Young, P., Brannagan, T. H., Adams, D., Van Damme, P., Thomas, F. P., Casanovas, C., Kafaie, J., Tard, C., Walter, M. C., Péréon, Y., Walk, D., Stino, A., de Visser, M., Verhamme, C., Amato, A., Carter, G., Magy, L., Statland, J. M., & Felice, K. (2021). A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A. Orphanet Journal of Rare Diseases, 16(1). https://doi.org/10.1186/s13023-021-02040-8
Authors:
Shahram Attarian
Peter Young
Thomas H. Brannagan
David Adams
Philip Van Damme
Florian P. Thomas
Carlos Casanovas
Céline Tard
Maggie C. Walter
Yann Péréon
David Walk
Amro Stino
Marianne de Visser
Camiel Verhamme
Anthony Amato
Gregory Carter
Laurent Magy
Jeffrey M. Statland
Kevin Felice
Affiliated Authors:
Thomas H. Brannagan
Author Keywords:
charcot–marie–tooth
cmt1a
neuromuscular disorder
overall neuropathy limitations scale
pmp22
pxt3003
randomized controlled trial
Publication Type:
Article
Unique ID:
10.1186/s13023-021-02040-8
PMID:
Publication Date:
Data Source:
Scopus

Record Created: